Simply Wall St.
BridgeBio Pharma (BBIO) Valuation After Attruby-Driven Earnings Beat and Renewed Analyst Support
📈
AI Sentiment
Highly Positive
9/10
- Home
- BBIO
as of 12-18-2025 2:27pm EST
$74.42
+$0.40
+0.54%
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Chart Type:
Time Range:
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 14.4B | IPO Year: | 2019 |
| Target Price: | $76.24 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $25.34 - $76.51 | Next Earning Date: | 10-29-2025 |
| Revenue: | $353,780,000 | Revenue Growth: | 62.46% |
| Revenue Growth (this year): | 128.44% | Revenue Growth (next year): | 76.14% |
AI-Powered BBIO Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 20 hours ago
AI Recommendation
hold
Model Accuracy: 81.58%
81.58%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of BridgeBio Pharma Inc. (BBIO)
Kumar Neil
Sell
Chief Executive Officer
BBIO Dec 15, 2025
Avg Cost/Share
$74.92
Shares
30,011
Total Value
$2,239,902.15
Owned After
228,776
Apuli Maricel
Sell
Chief Accounting Officer
BBIO Dec 8, 2025
Avg Cost/Share
$74.26
Shares
2,000
Total Value
$148,520.00
Owned After
130,297
SEC Form 4
Kumar Neil
Sell
Chief Executive Officer
BBIO Dec 5, 2025
Avg Cost/Share
$73.40
Shares
40,000
Total Value
$2,932,563.10
Owned After
228,776
Kumar Neil
Sell
Chief Executive Officer
BBIO Dec 4, 2025
Avg Cost/Share
$74.13
Shares
40,000
Total Value
$2,975,912.79
Owned After
228,776
Kumar Neil
Sell
Chief Executive Officer
BBIO Nov 20, 2025
Avg Cost/Share
$65.86
Shares
26,156
Total Value
$1,722,223.69
Owned After
228,776
Scott Randal W.
Sell
Director
BBIO Nov 17, 2025
Avg Cost/Share
$66.57
Shares
10,000
Total Value
$666,465.10
Owned After
17,788
Trimarchi Thomas
Sell
President and CFO
BBIO Nov 17, 2025
Avg Cost/Share
$66.52
Shares
16,934
Total Value
$1,125,404.42
Owned After
382,830
Valantine Hannah
Sell
Director
BBIO Nov 12, 2025
Avg Cost/Share
$66.07
Shares
25,484
Total Value
$1,683,727.88
Owned After
7,465
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Kumar Neil | BBIO | Chief Executive Officer | Dec 15, 2025 | Sell | $74.92 | 30,011 | $2,239,902.15 | 228,776 | |
| Apuli Maricel | BBIO | Chief Accounting Officer | Dec 8, 2025 | Sell | $74.26 | 2,000 | $148,520.00 | 130,297 | |
| Kumar Neil | BBIO | Chief Executive Officer | Dec 5, 2025 | Sell | $73.40 | 40,000 | $2,932,563.10 | 228,776 | |
| Kumar Neil | BBIO | Chief Executive Officer | Dec 4, 2025 | Sell | $74.13 | 40,000 | $2,975,912.79 | 228,776 | |
| Kumar Neil | BBIO | Chief Executive Officer | Nov 20, 2025 | Sell | $65.86 | 26,156 | $1,722,223.69 | 228,776 | |
| Lo Andrew | BBIO | Director | Nov 18, 2025 | Sell | $65.64 | 55,000 | $3,613,069.28 | 50,583 | |
| Scott Randal W. | BBIO | Director | Nov 17, 2025 | Sell | $66.57 | 10,000 | $666,465.10 | 17,788 | |
| Lo Andrew | BBIO | Director | Nov 17, 2025 | Sell | $66.84 | 40,599 | $2,706,593.15 | 50,583 | |
| Trimarchi Thomas | BBIO | President and CFO | Nov 17, 2025 | Sell | $66.52 | 16,934 | $1,125,404.42 | 382,830 | |
| Valantine Hannah | BBIO | Director | Nov 12, 2025 | Sell | $66.07 | 25,484 | $1,683,727.88 | 7,465 |
Latest BridgeBio Pharma Inc. News
BBIO Breaking Stock News: Dive into BBIO Ticker-Specific Updates for Smart Investing
Compare BBIO vs Leading Stocks
See how BBIO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BBIO BridgeBio Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.